Natco Pharma Ltd.

NATCOPHARM

₹806.55

1.38% (11.0)

Market Cap

₹14,457 Cr.

P/E

8.52

Key Ratios

Edit Ratio's

Market cap

14,457 Cr

8.52

Prom Holding

49.56 %

ROE (%)

24.79

ROCE (%)

30.32

Div Yield (%)

0.62

Sales

4,395 Cr

OPM (%)

44.64 %

Debt to Equity

0.04

Edit Ratio's

About

Natco Pharma Limited is a vertically integrated pharmaceutical company with a focus on researc… Read more

Low

727

52W Range

High

1505

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

10 Yes

Positive for this company

3 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Promoter Holding

Promoter has not sold any shares in the last 90 days
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Current vs Historic Valuation

Company is trading at a discount to 3yr historic valuations
Debt

Company should not have issues servicing its debt
Sales Growth

Sales of the company has grown at a good pace
ROE

Financial leverage has increased roe over 10 years
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Market Share

0.07 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

0.74 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

16.71 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

0.11 %

(as of Nov 21)

Historic

Blood Related - Market Share

0.56 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

30 %

(as of Mar 19)

Source/Historic

Copaxone - Market Share

0 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

0.01 %

(as of Jul 21)

Historic

Neurological - Market Share

0.38 %

(as of Nov 21)

Historic

Pain - Market Share

0.47 %

(as of Jul 22)

Historic

Pharmaceutical Sector - Market Share

0.30 %

(as of May 21)

Historic

Respiratory - Market Share

34.62 %

(as of May 19)

Historic

Urology - Market Share

Revenue mix

Product Wise Break-Up

Segment Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up - Formulation

Location Wise Break-Up

Therapeutic Area Break-Up - Formulation

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Domestic Sales Growth - YoY (%)
Source
US DMF Filings (.)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

Afinitor

Aubagio

Imbruvica

Kyprolis

Nexavar

Pomalyst

Revlimid

Sovaldi

Tarceva

Tykerb

Zytiga

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Suppliers

Laurus Labs Ltd.
Shaily Engineering Plastics Ltd.
Take Solutions Ltd.

FAQs on Natco Pharma Ltd. Business

What does Natco Pharma do?

Natco Pharma Limited is a vertically integrated pharmaceutical company that focuses on developing, manufacturing, and marketing pharmaceutical products, along with offering contract manufacturing services and crop health sciences division.

Who are the competitors of Natco Pharma?

Natco Pharma major competitors are Caplin Point Lab, Jubilant Pharmova, Alembic Pharma, Sanofi India, Procter&Gamble Healt, Strides Pharma Scien, Marksans Pharma.
Market Cap of Natco Pharma is ₹14,457 Crs.
While the median market cap of its peers are ₹10,837 Crs.

Is Natco Pharma financially stable compared to its competitors?

Natco Pharma seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Oversold on RSI Basis

Stocks with RSI of less than 30.

Run Query

Ben Graham Stock Screener

Benjamin Graham, a pioneer in value investing and mentor to Warren Buffett, advocated for buying stocks trading signifi…

Run Query

Superstar Favourites

Companies where superstar investors like Rakesh Jhunjhunwala, Asish Kacholia have invested

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	May Aug	Sep Dec	Mar Jun Sep Dec	Jun Sep	Mar Jun Sep Dec	Mar Jun Sep Dec						Sep
Investor Presentation	May Jul Aug	Feb Mar Jun Sep Dec	Mar Jun Sep Dec	Feb Mar Jun Aug Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Dec	Mar Jun Sep Dec	Mar Sep Dec	Mar Jun Sep Dec	Sep Dec	Mar Sep
Conference Call	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Natco Pharma Ltd.

Natco Pharma: Business Model Simplified - JST Investments

Chasing Optionalities - SOIC

View the discussion on ValuePickr

Natco Pharma: Chasing Optionalities - Ankush Agrawal

Interview with Mr Rajeev Nannapaneni, Vice Chairman & CEO at Natco Pharma - Moneylife

Business Analysis Of Natco Pharma - Value Educator

NatcoPharma - Complex generics focused manufacturer - Value Educator

Natco Pharma: Imminent Growth Cycle (?) - ValuePickr

A Deep Dive Into Natco Pharma - Numbers and Narratives

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Natco Pharma Ltd.

Natco Pharma Ltd.

Key Ratios

About

Timeline

Company Timeline

10 Yes

3 Neutral

4 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Depreciation Effect

Other Income

Pledge

Promoter Holding

Retail Holding

Revenue Recognition

Price & Performance

Capex vs ROCE

Share price

Working Capital

Current vs Historic Valuation

Debt

Sales Growth

ROE

Balance Sheet Strength

Margin Stability

ROCE Strength

Product Wise Break-Up

UNLOCK PREMIUM

Segment Break-Up

UNLOCK PREMIUM

Therapeutic Area Wise Break-Up - Domestic

UNLOCK PREMIUM

Location Wise Break-Up - Formulation

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Break-Up - Formulation

UNLOCK PREMIUM

Operating Profit Break-Up

UNLOCK PREMIUM

Asset Break-Up

UNLOCK PREMIUM

What does Natco Pharma do?

Who are the competitors of Natco Pharma?

Is Natco Pharma financially stable compared to its competitors?

SIGN UP FOR FREE